Accessibility Menu
Sino Biopharmaceutical logo

Sino Biopharmaceutical(SEHK) 1177

Market CapHK$90.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)+37,695%
5 Year-21%
1 Year-31%
1 Month+16%
HK$5.23
+2.75%
+0.14Today
Sino Biopharmaceutical last closing stock price
MetricPriceDate
Last closeHKD 5.232026-07-29
Sino Biopharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.24%HKD 5.352026-07-22
1 month+16.48%HKD 4.492026-06-29
3 month-3.51%HKD 5.422026-04-30
Year to date-15.37%HKD 6.182025-12-31
1 year-30.73%HKD 7.552025-07-29
3 year+46.09%HKD 3.582023-07-28
5 year-20.76%HKD 6.602021-07-30
Since inception+37,695.14%HKD 0.012000-09-29

Sino Biopharmaceutical Financials at a Glance

Market Cap

HK$90.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥31.83B

Net Income (TTM)

CN¥2.34B

EPS (TTM)

HK$0.14

P/E Ratio

36.83

Dividend

HK$0.10

Beta (Volatility)

0.06 (Low)

Price

HK$5.23

Volume

64,169,085

Open

HK$5.15

Previous Close

HK$5.09

Daily Range

HK$5.04 - HK$5.24

52-Week Range

HK$4.19 - HK$9.12

Estimated Earnings Date

Aug 26, 2026

1177 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a leading pharmaceutical company based in Hong Kong, specializing in research and development of innovative medicines. The company operates through various segments, focusing on modernized Chinese medicines and chemical medicines, with a strong emphasis on oncology and liver disease treatments.

Products and Services
  • Oncology medicines, including anlotinib and penpulimab injections
  • Liver disease medications, such as magnesium isoglycyrrhizinate and entecavir
  • Respiratory system medicines, including budesonide and colistimethate sodium
Growth Outlook
  • Strong demand for oncology drugs is expected to drive revenue growth
  • Expansion into international markets may enhance global presence
  • Investment in R&D is projected to yield new product launches
Financial Highlights
  • Recent quarterly revenue of 7.13 billion CNY reflects stable performance
  • Trailing twelve months (TTM) net profit margin stands at 7.36%
  • Current ratio of 1.37 indicates solid short-term financial health
Sino Biopharmaceutical Limited has established itself as a significant player in the pharmaceutical industry, particularly in the oncology and liver disease sectors. The company's diverse product portfolio and commitment to research and development position it well for future growth. Recent financial performance shows resilience, with a stable revenue stream and a healthy net profit margin. The focus on expanding market reach and investing in innovative treatments further enhances the company's growth potential. Investors may find Sino Biopharmaceutical Limited an intriguing opportunity within the healthcare sector.
AI Generated • Jul 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

21,435

CEO

S Y Tse

Website

www.sinobiopharm.com

Headquarters

Hong Kong, HK

1177 Financials

Key Financial Metrics (TTM)

Gross Margin

82.07%

Operating Margin

21.84%

Net Income Margin

7.36%

Return on Equity

7.32%

Return on Capital

14.87%

Return on Assets

3.08%

Earnings Yield

2.72%

Dividend Yield

1.96%

Payout Ratio

64.12%

Stock Overview

Market Cap

HK$90.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.81B

Volume

64.17M

Avg. Volume

95.99M

Financials (TTM)

Gross Profit

CN¥26.13B

Operating Income

CN¥6.95B

EBITDA

CN¥7.26B

Operating Cash Flow

CN¥9.29B

Capital Expenditure

-CN¥1.24B

Free Cash Flow

CN¥8.05B

Cash & ST Invst.

CN¥22.56B

Total Debt

CN¥16.07B

Sino Biopharmaceutical Performance Analysis

Sino Biopharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 30,265,258,690-6.5%
20232023-12-31CNY 28,950,294,474-4.3%
20242024-12-31CNY 31,297,377,8298.1%
20252025-12-31CNY 34,525,246,23110.3%
Sino Biopharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3135.3%
Q22025-06-30N/A
Q32025-09-30-18.9%
Q42025-12-31N/A
Sino Biopharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.14-84.0%
20232023-12-31CNY 0.14-1.6%
20242024-12-31CNY 0.11-23.7%
20252025-12-31CNY 0.1432.6%
Sino Biopharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31571.4%
Q22025-06-30N/A
Q32025-09-30-130.9%
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CN¥7.13B

+9.8%

Gross Profit

CN¥5.82B

+10.8%

Gross Margin

81.58%

N/A

Market Cap

HK$90.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$4.23M

N/A

Employees

21,435

N/A

Net Income

-CN¥522.62M

-316.6%

EBITDA

CN¥1.66B

+52.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CN¥22.56B

+54.5%

Total Debt

CN¥16.07B

+64.3%

Accounts Receivable

CN¥6.64B

+32.5%

Inventory

CN¥2.26B

-4.9%

Long Term Debt

CN¥7.65B

+267.8%

Short Term Debt

CN¥8.42B

+9.3%

Return on Assets

3.08%

N/A

Return on Invested Capital

13.69%

N/A

Free Cash Flow

CN¥2.58B

N/A

Operating Cash Flow

CN¥3.07B

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,401.99-0.00%
^DJIDJI
$51,943.58-0.02%
^IXICNASDAQ
$24,815.43-0.00%
BTCBitcoin
$64,239.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.27-0.09%
INTCIntel
$82.27-0.05%
NVDANvidia
$190.52-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.88-0.06%

Questions About 1177

What is the current price of Sino Biopharmaceutical?

Sino Biopharmaceutical is trading at HK$5.23 per share.

What is the 52-week range for Sino Biopharmaceutical?

Over the past 52 weeks, Sino Biopharmaceutical has traded between HK$4.19 and HK$9.12.

How much debt does Sino Biopharmaceutical have?

As of the most recent reporting period, Sino Biopharmaceutical reported total debt of CN¥17.90B.

How much cash does Sino Biopharmaceutical have on hand?

Sino Biopharmaceutical reported CN¥8.23B in cash and cash equivalents in its most recent financial results.

What is Sino Biopharmaceutical’s dividend yield?

Sino Biopharmaceutical currently has a dividend yield of 1.96%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services